Molecular Oncology Laboratory

The molecular oncology laboratory is part of the Molecular Diagnostics Section in charge of testing for molecular markers important in many neoplastic conditions. Our current testing menu includes:

  • BCR::ABL1 quantitative, p210 major breakpoint
  • BCR::ABL1 quantitative, p190 minor breakpoint
  • PML::RARA, quantitative, bcr 1 (long) and bcr 3 (short) forms
  • BRAF mutational analysis
  • EGFR mutational analysis
  • KRAS mutational analysis
  • NRAS mutational analysis
  • Immunoglobulin heavy chain gene rearrangement (B-cell clonality)
  • T-cell receptor gamma gene rearrangement (T-cell clonality)
  • FLT3 mutation analysis (ITD and TKD mutations)
  • Next-Generation Sequencing (NGS) for myeloid neoplasms
  • Next-Generation Sequencing (NGS) for solid tumors

All specimens submitted for analysis must be accompanied by a requisition form.

Samples may be submitted in several ways:

  • Formalin-fixed paraffin embedded (FFPE) tissues, on either glass slides or block (with H&E slide and specified percent tumor).
  • Peripheral blood/ bone marrow samples (should be collected in EDTA only).
  • Body fluid samples (require a dedicated sample).
  • Tubes that have been opened and samples for obtained for other tests will be considered on a case-by-case basis (at the director's discretion).

Normal turnaround time is estimated to be 3-5 days depending upon the day the sample is received and the test being performed.

Please contact Dr. Giovanni Insuasti 336-716-9405 for any related questions.